ArticleVeterinary sciences2021
A Retrospective Multicentric Study of Electrochemotherapy in the Treatment of Feline Nasal Planum Squamous Cell Carcinoma.
Article in Veterinary sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Electrical resistance measurement in feline cutaneous squamous cell carcinoma treated with electrochemotherapy: a pilot study.Scientific reports · 2026Article
- vetInspECT: a platform for the multicentric evaluation of treatment response after electrochemotherapy in veterinary oncology - feline tumors.BMC veterinary research · 2026Article
- A retrospective study on cats with incompletely or marginally excised sarcomas treated with a bleomycin-only electrochemotherapy protocol: 66 cases.Frontiers in veterinary science · 2026Article
- Diagnosis and Surgical Treatment of Nasal Squamous Cell Carcinoma in a Vietnamese Pot-Bellied Pig.Animals : an open access journal from MDPI · 2025Article
- Feline Injection-Site Sarcoma Treated with Surgery, Orthovoltage Radiotherapy, and Electrochemotherapy. A Retrospective Series of 72 Cases.Bioelectricity · 2025Article
- Efficacy of gabapentin as pain management of TScientific reports · 2025Article
- Electrochemotherapy is effective in the treatment of early-stage feline cutaneous squamous cell carcinoma.Journal of feline medicine and surgery · 2025Article
- Description of outcome and adverse events in 21 cats with locally advanced nasal planum squamous cell carcinoma treated with electrochemotherapy.Journal of feline medicine and surgery · 2024Article
- Electroporation in Translational Medicine: From Veterinary Experience to Human Oncology.Cancers · 2024Review
- Perineural invasion as a predictor of local recurrence in cats with squamous cell carcinoma treated with electrochemotherapy.Frontiers in veterinary science · 2024Article
- Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.Scientific reports · 2023Article
- Article
- Electrochemotherapy using thin-needle electrode improves recovery in feline nasal planum squamous cell carcinoma - a translational model.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Electrochemotherapy as a treatment option for feline nasal melanoma.JFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline squamous cell carcinoma (SCC) is currently treated with surgery, radiation therapy and electrochemotherapy (ECT). Both the efficacy and/or safety of ECT were evaluated as a sole therapy with bleomycin to treat feline nasal planum SCC (npSCC). Sixty-one cats were enrolled. Local treatment response was evaluated as complete remission (CR), partial remission (PR) or stable disease (SD). Recurrence rate (RR), disease-free interval (DFI) and progression free survival (PFS) were calculated. A six-point scale was used for ECT toxicity. The median tumor size was 1.5 cm. CR was achieved in 65.6% of cases, PR in 31.1% and SD in 3.3%. The overall response rate was 96.7%, RR was 22.5%, median DFI was 136 days, and median PFS was 65.5 days. ECT toxicity was ≤2 in 51% of cats. Tumor recurrence/progression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.